
Axsome Therapeutics Inc (NASDAQ:AXSM) shares rallied 40% on Monday morning after the company received some positive news from the U.S. Food and Drug Administration regarding its AXS-05 novel treatment for MDD (depression).
What Happened? Axsome filed an 8K on Monday morning reporting the FDA has proposed a product label for ASX-05. While the market's initial reaction to the news was extremely positive, Bank of America analyst Jason Gerberry remains skeptical about ASX-05's potential commercial success.